Theme	Session Title	Presentation No.	Abstract No.	Lecture title	Speaker	Country
Tumor-type specific Sessions	Medulloblastoma (basic)	MEDB-IS-01	SPKR-05	Medulloblastomics 2020: biological and clinical insights from 1,000s of patients	Paul Northcott	USA
		MEDB-O-02	MBRS-24	Functional characterization of IKBKAP/ELP1 as a novel SHH medulloblastoma predisposition gene	Jesus Garcia Lopez	USA
		MEDB-O-03	MBRS-59	Single-cell whole-genome sequencing dissects intra-tumoural genomic heterogeneity and clonal evolution in childhood medulloblastoma	Marina Danilenko	UK
		MEDB-O-04	MBRS-12	A transposon mutagenesis screen identifies Rreb1 as a driver for Group 3 medulloblastoma	Robert Wechsler-Reya	USA
		MEDB-O-05	MBRS-26	CDK7 mediated transcriptional processivity of DNA Repair networks regulates sensitivity to radiation in Myc driven medulloblastoma	Bethany Veo	USA
		MEDB-O-06	MBRS-72	MiR-212 functions as a tumor suppressor gene in group 3 medulloblastoma via targeting nuclear factor I/B (NFIB)	Sidharth Mahapatra	USA
		MEDB-O-07	MBRS-73	An exploratory analysis looking at the association of germline coding mutations with impaired development and adaptive behavior function in pediatric medulloblastoma patients treated on Head Start 4	Jessica Fleming	USA
		MEDB-P-08	MBRS-03	Single nucleus transcriptome profiles from human developing cerebellum reveal potential cellular origins of medulloblastoma brain tumors	Konstantin Okonechnikov	Germany
		MEDB-P-09	MBRS-60	The actionable genomic landscape of relapsed medulloblastoma is defined by maintenance and acquisition of driver events	Stacey Richardson	UK
		MEDB-P-10	MBRS-16	MYC regulated long noncoding RNA lnc-HLX-2-7 is a putative molecular marker and a therapeutic target for Group 3 medulloblastomas in children	Ranjan Perera	USA
		MEDB-P-11	MBRS-20	CSF-derived circulating tumor DNA as a biomarker for disease progression and tumor evolution in medulloblastoma	Anthony Pak-Yin Liu	USA
		MEDB-P-12	MBRS-38	Molecular classification and clinical characteristics of 236 medulloblastomas in Japan	Yonehiro Kanemura	Japan
		MEDB-P-13	MBRS-46	Charting neoplastic and immune cell heterogeneity in human and GEM models of medulloblastoma using scRNAseq	Andrew Donson	USA
		MEDB-P-14	MBRS-54	Poor survival in replication repair deficient hypermutant medulloblastoma and CNS embryonal tumors: A Report from the International RRD Consortium	Anirban Das	Canada
		MEDB-P-15	MBRS-68	Single nucleus RNA-sequencing deciphers intratumoral heterogeneity in medulloblastoma with extensive nodularity (MBEN)	Kristian Pajtler	Germany
		MEDB-P-16	MBRS-17	Examining the role of LHX9 in group 3 medulloblastoma	Sarah Injac	USA
		MEDB-P-17	MBRS-48	Identification of novel therapeutic approaches for MYC-driven medulloblastoma	Kübra Taban	Germany
		MEDB-P-18	MBRS-53	Control of medulloblastoma vasculature by a regulator of neurogenesis	Shavali Shaik	USA
		MEDB-P-19	MBRS-67	Role of cyclin dependent kinase-9 in Myc-enhanced medulloblastoma	Krishna Madhavan	USA
		MEDB-P-20	MBRS-56	Re-evaluation of leptomeningeal metastasis in medulloblastoma with magnetic resonance imaging, related symptoms and cerebrospinal fluid metabolomic profiles	Hyeon Jin Park	Korea
		MEDB-P-21	MBRS-66	Cost-effective method to incorporate molecular classification of medulloblastoma into a Latin-American clinical trial	Sidnei Epelman	Brazil
		MEDB-P-22	MBRS-19	Synergism of HDAC and PARP inhibitors in MYC-driven Group 3 medulloblastoma cells	Till Milde	Germany
		MEDB-P-23	MBRS-33	Temporary restoration of p53 activity during fractionated radiotherapy in a Group3 Medulloblastoma GEMM represents a powerful tool for radiobiology studies	Alaide Morcavallo	UK
		MEDB-P-25	MBRS-47	Rapid molecular subgrouping of medulloblastoma based on DNA methylation by nanopore sequencing	Julien Masliah-Planchon	France
		MEDB-P-26	MBRS-70	Functional dependency between REST and DNMT1 in medulloblastoma	Shinji Maegawa	USA
		MEDB-P-27	MBRS-04	Medulloblastoma detection by blood test	Ruty Mehrian-Shai	Israel
		MEDB-P-28	MBRS-10	Quiescent SOX9-positive cells behind MYC driven medulloblastoma recurrence	Miao Zhao	Sweden
		MEDB-P-29	MBRS-13	MiR-1253 Potentiates Cisplatin Response in Pediatric Medulloblastoma by regulating ferroptosis	Sidharth Mahapatra	USA
		MEDB-P-30	MBRS-22	Significance of RNF213 in tumorgenicity of medulloblastoma	Yohei Mineharu	Japan
		MEDB-P-31	MBRS-42	YB-1 - a novel therapeutic target in high-risk medulloblastoma?	Louisa Taylor	UK
		MEDB-P-32	MBRS-45	TWIST1 and ABCB1 are functional determinants of metastasis in medulloblastoma	Alice Cardall	UK
		MEDB-P-33	MBRS-57	Identification of MYC-dependent therapeutic vulnerabilities for targeting Group 3 medulloblastoma	Gemma Llargués-Sistac	UK
		MEDB-P-34	MBRS-63	The role of the SWI/SNF complex subunit SMARCD3 in medulloblastoma	Baoli Hu	USA
		MEDB-P-35	MBRS-69	Metabolite profiling of SHH medulloblastoma identifies a subset of childhood tumours enriched for high-risk molecular biomarkers and clinical features	Christopher Bennett	UK
		MEDB-P-36	MBRS-71	Ataxia telangiectasia and Rad3-related protein attenuates DNA damage and is a therapeutic target in Myc-driven medulloblastoma	Krishna Madhavan	USA
		MEDB-P-37	MBRS-27	Exosomes carry distinct miRNAs that drive medulloblastoma progression	Hannah Jackson	UK
		MEDB-P-38	MBRS-43	Elucidating how novel extracellular matrix subtypes differentially impact the survival of medulloblastoma subgroups	James Johnson	UK
		MEDB-P-39	MBRS-62	Curaxin CBL0137 inhibits the viability of cancerous cells in pre-clinic models of MYC-amplified medulloblastoma	Jie Ma	China
		MEDB-P-40	MBRS-64	Study of arginine methyl transferases in medulloblastoma	Donghang Cheng	USA
		MEDB-P-41	MBRS-01	Dissecting regulators of the aberrant post-transcriptional landscape in MYC-amplified Group 3 medulloblastoma	Michelle Kameda-Smith	Canada
		MEDB-P-42	MBRS-18	Tumor suppressor p53 defines the therapeutic responses in treatment of medulloblastoma	Meena Jhanwar-Uniyal	USA
		MEDB-P-43	MBRS-37	Recurrent activating mutations of AKT genes in WNT-activated medulloblastomas	Julien Masliah-Planchon	France
		MEDB-P-44	MBRS-39	MAP4K4 controls pro-invasive signaling in medulloblastoma cells	Martin Baumgartner	Switzerland
		MEDB-P-45	MBRS-51	Mutations in BRPF1 found in SHH Medulloblastoma prevent interaction with TP53 and leads to radioresistance in vitro	Patricia Benites Goncalves da Sliva	Germany
		MEDB-P-46	MBRS-08	Sonic Hedgehog signaling primes cerebellar granule neuron progenitors, the cell of origin for medulloblastoma, for apoptosis by inducing pro apoptotic BIM	Abigail Cleveland	USA
		MEDB-P-47	MBRS-14	Integrating clinical and genomic characteristics in pediatric medulloblastoma subtypes in a single cohort in Taiwan	Kuo-Sheng Wu	Taiwan
		MEDB-P-48	MBRS-23	Significance of mi-R33 in generation and progression of medulloblastoma	Yasuzumi Matsui	Japan
		MEDB-P-49	MBRS-28	Exosomes drive medulloblastoma metastasis in a MMP2 and EMMPRIN dependent manner	Hannah Jackson	UK
		MEDB-P-50	MBRS-65	FBXW7 acts a tumor suppressor in MYC-driven medulloblastoma by controlling a feed-forward regulatory loop of PLK1 and MYC	Dong Wang	USA
		MEDB-P-51	MBRS-02	BET bromodomain protein-kinase inhibitor combinations for the treatment of medulloblastoma	Nagi Ayad	USA
		MEDB-P-52	MBRS-32	Topoisomerase II β induces neuronal, but not glial, differentiation in medulloblastoma	Hiroaki Miyahara	Japan
		MEDB-P-53	MBRS-61	Molecular sub-grouping of pediatric medulloblastoma: Correlation with clinical and histological features, a single institutional study	Gauri Deshpande	India
		MEDB-P-54	MBRS-29	Prospective molecular profiling In pediatric medulloblastoma patients enrolled on the "Head Start 4" protocol	Jessica Fleming	USA
		MEDB-P-55	MBRS-31	Combining irradiation and anti-CD47 to enhance the treatment of group 3 medulloblastoma	Osama Youssef	USA
		MEDB-P-56	MBRS-06	Gli3 induces neuronal differentiation in WNT- and SHH- activated medulloblastoma	Manabu Natsumeda	Japan
		MEDB-P-57	MBRS-21	Clinical aggressiveness of TP53-wild type Sonic Hedgehog medulloblastoma with MYCN amplification	Yuichi Mitani	Japan